The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response?
Abstract
The advent of biological therapy has revolutionized inflammatory bowel disease (IBD) care. Nonetheless, not all patients require biological therapy. Selection of patients depends on clinical characteristics, previous response to other medical therapy, and comorbid conditions. Availability, reimbursement guidelines, and patient preferences guide the choice of first-line biological therapy for luminal Crohn's disease (CD). Infliximab (IFX) has the most extensive clinical trial data, but other biological agents (adalimumab (ADA), certolizumab pegol (CZP), and natalizumab (NAT)) appear to have similar benefits in CD. Steroid-refractory, steroid-dependent, or complex fistulizing CD are indications for starting biological therapy, after surgical drainage of any sepsis. For fistulizing CD, the efficacy of IFX for inducing fistula closure is best documented. Unique risks of NAT account for its labeling as a second-line biological agent in some countries. Patients who respond to induction therapy benefit from systematic re-treatment. The combination of IFX with azathioprine is better than monotherapy for induction of remission and mucosal healing up to 1 year in patients who are naïve to both agents. Whether this applies to other agents remains unknown. IFX is also effective for treatment-refractory, moderate, or severely active ulcerative colitis. Patients who have a diminished or loss of response to anti-tumor necrosis factor (TNF) therapy may respond to dose adjustment of the same agent or switching to another agent. Careful consideration should be given to the reasons for loss of response. There are insufficient data to make recommendations on when to stop anti-TNF therapy. Preliminary evidence suggests that a substantial proportion of patients in clinical remission for >1 year, without signs of active inflammation can remain in remission after stopping treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Self-citationInfliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050516 · Cited by 3,902
Self-citationInfliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Colombel, J. F., Sandborn, W. J., Reinisch, W., Mantzaris, G. J., Kornbluth, A., Rachmilewitz, D., Lichtiger, S., D'Haens, G., Diamond, R. H., Broussard, D. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0904492 · Cited by 3,143
Self-citationTargan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Self-citationInfliximab for the Treatment of Fistulas in Patients with Crohn's Disease
Present, D. H., Rutgeerts, P., Targan, S., Hanauer, S. B., Mayer, L., van Hogezand, R. A., Podolsky, D. K., Sands, B. E., Braakman, T., DeWoody, K. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905063401804 · Cited by 2,752
Self-citationColombel, J., Sandborn, W. J., Rutgeerts, P., Enns, R., Hanauer, S. B., Panaccione, R., Schreiber, S., Byczkowski, D., Li, J., Kent, J. D., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.041 · Cited by 2,245
Self-citationInfliximab Maintenance Therapy for Fistulizing Crohn's Disease
Sands, B. E., Anderson, F. H., Bernstein, C. N., Chey, W. Y., Feagan, B. G., Fedorak, R. N., Kamm, M. A., Korzenik, J. R., Lashner, B. A., Onken, J. E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030815 · Cited by 2,226
Self-citationInfluence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
Self-citationHanauer, S. B., Sandborn, W. J., Rutgeerts, P., Fedorak, R. N., Lukas, M., MacIntosh, D., Panaccione, R., Wolf, D., & Pollack, P. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.030 · Cited by 1,715
Self-citationNational Cooperative Crohn's Disease Study: Results of drug treatment
Summers, R. W., Switz, D. M., Sessions, J. T., Becktel, J. M., Best, W. R., Kern, F., & Singleton, J. W. (1979) · Gastroenterology · doi:10.1016/0016-5085(79)90385-8 · Cited by 1,239
D'Haens, G., Baert, F., van Assche, G., Caenepeel, P., Vergauwe, P., Tuynman, H., De Vos, M., van Deventer, S., Stitt, L., Donner, A., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60304-9 · Cited by 1,231
Self-citationFaubion, W. A., Loftus, E. V., Harmsen, W. S., Zinsmeister, A. R., & Sandborn, W. J. (2001) · Gastroenterology · doi:10.1053/gast.2001.26279 · Cited by 1,144
Self-citationCertolizumab Pegol for the Treatment of Crohn's Disease
Sandborn, W. J., Feagan, B. G., Stoinov, S., Honiball, P. J., Rutgeerts, P., Mason, D., Bloomfield, R., & Schreiber, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067594 · Cited by 1,143
Self-citationMucosal Healing in Inflammatory Bowel Disease: Results From a Norwegian Population-Based Cohort
Frøslie, K. F., Jahnsen, J., Moum, B. A., & Vatn, M. H. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.051 · Cited by 1,121
Järnerot, G., Hertervig, E., Friis-Liby, I., Blomquist, L., Karlén, P., Grännö, C., Vilien, M., Ström, M., Danielsson, Å., Verbaan, H., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.003 · Cited by 1,089
Rutgeerts, P., D'Haens, G., Targan, S., Vasiliauskas, E., Hanauer, S. B., Present, D. H., Mayer, L., Van Hogezand, R. A., Braakman, T., DeWoody, K. L., et al. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70332-x · Cited by 1,080
Self-citationMaintenance Therapy with Certolizumab Pegol for Crohn's Disease
Schreiber, S., Khaliq-Kareemi, M., Lawrance, I. C., Thomsen, O. Ø., Hanauer, S. B., McColm, J., Bloomfield, R., & Sandborn, W. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062897 · Cited by 1,043
Self-citationTreatment of Crohn's Disease with 6-Mercaptopurine: A Long-Term, Randomized, Double-Blind Study
Present, D. H., Korelitz, B. I., Wisch, N., Glass, J. L., Sachar, D. B., & Pasternack, B. S. (1980) · New England Journal of Medicine · doi:10.1056/nejm198005013021801 · Cited by 1,042
Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial
Sandborn, W. J., Hanauer, S. B., Rutgeerts, P., Fedorak, R. N., Lukas, M., MacIntosh, D. G., Panaccione, R., Wolf, D., Kent, J. D., Bittle, B., et al. (2007) · Gut · doi:10.1136/gut.2006.106781 · Cited by 1,039
Self-citationRisk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease
Toruner, M., Loftus, E. V., Harmsen, W. S., Zinsmeister, A. R., Orenstein, R., Sandborn, W. J., Colombel, J., & Egan, L. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.012 · Cited by 1,017
Self-citationSandborn, W. J., Rutgeerts, P., Enns, R., Hanauer, S. B., Colombel, J.-F., Panaccione, R., D'Haens, G., Li, J., Rosenfeld, M. R., Kent, J. D., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00159 · Cited by 965
Self-citationLaboratory markers in IBD: useful, magic, or unnecessary toys?
Vermeire, S., Van Assche, G., & Rutgeerts, P. (2006) · Gut · doi:10.1136/gut.2005.069476 · Cited by 952
Self-citationComparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease
Rutgeerts, P., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.11.014 · Cited by 943
Self-citationNatalizumab Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Colombel, J. F., Enns, R., Feagan, B. G., Hanauer, S. B., Lawrance, I. C., Panaccione, R., Sanders, M., Schreiber, S., Targan, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043335 · Cited by 927
Self-citationVan Assche, G., Dignass, A., Reinisch, W., van der Woude, C. J., Sturm, A., De Vos, M., Guslandi, M., Oldenburg, B., Dotan, I., Marteau, P., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.09.009 · Cited by 894
Self-citationHyams, J., Crandall, W., Kugathasan, S., Griffiths, A., Olson, A., Johanns, J., Liu, G., Travers, S., Heuschkel, R., Markowitz, J., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.12.003 · Cited by 877
Beaugerie, L., Seksik, P., Nion–Larmurier, I., Gendre, J., & Cosnes, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.019 · Cited by 860
Rahier, J. F., Ben-Horin, S., Chowers, Y., Conlon, C., De Munter, P., D'Haens, G., Domènech, E., Eliakim, R., Eser, A., Frater, J., et al. (2009) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.02.010 · Cited by 738
Self-citationMarkowitz, J., Grancher, K., Kohn, N., Lesser, M., & Daum, F. (2000) · Gastroenterology · doi:10.1053/gast.2000.18144 · Cited by 716
Clinical, biological, and endoscopic picture of attacks of Crohn's disease
Modigliani, R., Mary, J.-Y., Simon, J.-F., Cortot, A., Soule, J.-C., Gendre, J.-P., & Rene, E. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90002-i · Cited by 699
Frequency of glucocorticoid resistance and dependency in Crohn's disease.
Munkholm, P., Langholz, E., Davidsen, M., & Binder, V (1994) · Gut · doi:10.1136/gut.35.3.360 · Cited by 654
Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial
Targan, S. R., Feagan, B. G., Fedorak, R. N., Lashner, B. A., Panaccione, R., Present, D. H., Spehlmann, M. E., Rutgeerts, P. J., Tulassay, Z., Volfova, M., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.024 · Cited by 614
Self-citationMaser, E. A., Villela, R., Silverberg, M. S., & Greenberg, G. R. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.06.025 · Cited by 613
Infliximab Prevents Crohn's Disease Recurrence After Ileal Resection
Regueiro, M., Schraut, W., Baidoo, L., Kip, K. E., Sepulveda, A. R., Pesci, M., Harrison, J., & Plevy, S. E. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.10.051 · Cited by 601
Self-citationTravis, S. P. L., Stange, E. F., Lémann, M., Öresland, T., Chowers, Y., Forbes, A., D’Haens, G., Kitis, G., Cortot, A., Prantera, C., et al. (2006) · Gut · doi:10.1136/gut.2005.081950b · Cited by 597
Self-citationA Comparison of Budesonide with Prednisolone for Active Crohn's Disease
Rutgeerts, P., Lofberg, R., Malchow, H., Lamers, C., Olaison, G., Jewell, D., Danielsson, A., Goebell, H., Thomsen, O. O., Lorenz-Meyer, H., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409293311304 · Cited by 589
Schreiber, S., Rutgeerts, P., Fedorak, R. N., Khaliq–Kareemi, M., Kamm, M. A., Boivin, M., Bernstein, C. N., Staun, M., Thomsen, O. Ø., & Innes, A. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.06.064 · Cited by 580
Self-citationPeyrin–Biroulet, L., Deltenre, P., de Suray, N., Branche, J., Sandborn, W. J., & Colombel, J. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.03.014 · Cited by 577
Self-citationOral Budesonide for Active Crohn's Disease
Greenberg, G. R., Feagan, B. G., Martin, F., Sutherland, L. R., Thomson, A., Williams, C. N., Nilsson, L.-G., & Persson, T. (1994) · New England Journal of Medicine · doi:10.1056/nejm199409293311303 · Cited by 563
Self-citationEuropean evidence-based Consensus on the management of ulcerative colitis: Current management
Travis, S. P. L., Stange, E. F., Lémann, M., Øresland, T., Bemelman, W. A., Chowers, Y., Colombel, J. F., D'Haens, G., Ghosh, S., Marteau, P., et al. (2008) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2007.11.002 · Cited by 558
Self-citationStange, E. F., Travis, S. P. L., Vermeire, S., Reinisch, W., Geboes, K., Barakauskiene, A., Feakins, R., Fléjou, J. F., Herfarth, H., Hommes, D. W., et al. (2008) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2007.11.001 · Cited by 555
Self-citationRutgeerts, P., Diamond, R. H., Bala, M., Olson, A., Lichtenstein, G. R., Bao, W., Patel, K., Wolf, D. C., Safdi, M., Colombel, J. F., et al. (2006) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2005.08.011 · Cited by 548
Self-citationSeow, C. H., Newman, A., Irwin, S. P., Steinhart, A. H., Silverberg, M. S., & Greenberg, G. R. (2010) · Gut · doi:10.1136/gut.2009.183095 · Cited by 536
Schnitzler, F., Fidder, H., Ferrante, M., Noman, M., Arijs, I., Van Assche, G., Hoffman, I., Van Steen, K., Vermeire, S., & Rutgeerts, P. (2009) · Gut · doi:10.1136/gut.2008.155812 · Cited by 535
Self-citationInfliximab for the treatment of fistulas in patients with Crohn's disease
Ricart, E., & Sandborn, W. J. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70414-2 · Cited by 519
Self-citationVan Assche, G., Magdelaine–Beuzelin, C., D'Haens, G., Baert, F., Noman, M., Vermeire, S., Ternant, D., Watier, H., Paintaud, G., & Rutgeerts, P. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.004 · Cited by 495
Self-citationColorectal cancer risk and mortality in patients with ulcerative colitis
Langholz, E., Munkholm, P., Davidsen, M., & Binder, V. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)91163-x · Cited by 493
Afif, W., Loftus, E. V., Faubion, W. A., Kane, S. V., Bruining, D. H., Hanson, K. A., & Sandborn, W. J. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.9 · Cited by 486
Self-citationKarmiris, K., Paintaud, G., Noman, M., Magdelaine–Beuzelin, C., Ferrante, M., Degenne, D., Claes, K., Coopman, T., Van Schuerbeek, N., Van Assche, G., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.07.062 · Cited by 478
Self-citationColectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab
Sandborn, W. J., Rutgeerts, P., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Lu, J., Horgan, K., Rachmilewitz, D., Hanauer, S. B., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.06.061 · Cited by 473
Self-citationMagnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease
Van Assche, G. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)05909-9 · Cited by 457
Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
Abreu, M. T., Taylor, K. D., Lin, Y.-C., Hang, T., Gaiennie, J., Landers, C. J., Vasiliauskas, E. A., Kam, L. Y., Rojany, M., Papadakis, K. A., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.35393 · Cited by 428
Self-citationMucosal gene signatures to predict response to infliximab in patients with ulcerative colitis
Arijs, I., Li, K., Toedter, G., Quintens, R., Van Lommel, L., Van Steen, K., Leemans, P., De Hertogh, G., Lemaire, K., Ferrante, M., et al. (2009) · Gut · doi:10.1136/gut.2009.178665 · Cited by 408
Self-citationIntestinal cancer risk and mortality in patients with Crohn's disease
Munkholm, P., Langholz, E., Davidsen, M., & Binder, V. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)91068-s · Cited by 379
Feagan, B. G., Panaccione, R., Sandborn, W. J., D'Haens, G. R., Schreiber, S., Rutgeerts, P. J., Loftus, E. V., Lomax, K. G., Yu, A. P., Wu, E. Q., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.069 · Cited by 374
Self-citationLÉmann, M., Mary, J., Duclos, B., Veyrac, M., Dupas, J., Delchier, J. C., Laharie, D., Moreau, J., Cadiot, G., Picon, L., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.02.014 · Cited by 372
Self-citationAdalimumab for the treatment of fistulas in patients with Crohn’s disease
Colombel, J.-F., Schwartz, D. A., Sandborn, W. J., Kamm, M. A., D’Haens, G., Rutgeerts, P., Enns, R., Panaccione, R., Schreiber, S., Li, J., et al. (2009) · Gut · doi:10.1136/gut.2008.159251 · Cited by 365
Self-citationEffect of Cigarette Smoking on Recurrence of Crohn's Disease
Sutherland, L. R., Ramcharan, S., Bryant, H., & Fick, G. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90324-t · Cited by 362
Sands, B. E., Blank, M. A., Patel, K., & Van Deventer, S. J. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00414-8 · Cited by 359
Self-citationFerrante, M., Henckaerts, L., Joossens, M., Pierik, M., Joossens, S., Dotan, N., Norman, G. L., Altstock, R. T., Van Steen, K., Rutgeerts, P., et al. (2007) · Gut · doi:10.1136/gut.2006.108043 · Cited by 292
Self-citationPredictors of severe Crohn's disease
Loly, C., Belaiche, J., & Louis, E. (2008) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520801957149 · Cited by 289
Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients
Ricart, E., Panaccione, R., Loftus, E. V., Tremaine, W. J., & Sandborn, W. J. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03612.x · Cited by 285
Self-citationThia, K. T., Mahadevan, U., Feagan, B. G., Wong, C., Cockeram, A., Bitton, A., Bernstein, C. N., & Sandborn, W. J. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20608 · Cited by 278
Self-citationSandborn, W. J., Hanauer, S., Loftus, E. V., Tremaine, W. J., Kane, S., Cohen, R., Hanson, K., Johnson, T., Schmitt, D., & Jeche, R. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.40462.x · Cited by 276
Self-citationLouis, E. J., Vermeire, S. A. R. A., Rutgeerts, P., Vos, M. D., Gossum, A. V., Pescatore, P., Fiasse, R., Pelckmans, P. A., Reynaert, H., D’Haens, G., et al. (2002) · Scandinavian Journal of Gastroenterology · doi:10.1080/713786515 · Cited by 270
Self-citationLichtenstein, G. R., Yan, S., Bala, M., & Hanauer, S. (2004) · American Journal of Gastroenterology · doi:10.1046/j.1572-0241.2003.04010.x · Cited by 265
Self-citationWest, R. L., van der Woude, C. J., Hansen, B. E., Felt‐Bersma, R. J. F., van Tilburg, A. J. P., Drapers, J. A. G., & Kuipers, E. J. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02247.x · Cited by 256
Predictors of response to infliximab in patients with Crohn's disease
Parsi, M. A., Achkar, J., Richardson, S., Katz, J., Hammel, J. P., Lashner, B. A., & Brzezinski, A. (2002) · Gastroenterology · doi:10.1053/gast.2002.35390 · Cited by 252
Self-citationTopstad, D. R., Panaccione, R., Heine, J. A., Johnson, D. R. E., MacLean, A. R., & Buie, D. W. (2003) · Diseases of the Colon & Rectum · doi:10.1007/s10350-004-6611-4 · Cited by 244
Self-citationSchreiber, S., Colombel, J.-F., Bloomfield, R., Nikolaus, S., Schölmerich, J., Panés, J., & Sandborn, W. J. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.78 · Cited by 230
Self-citationInfliximab in Crohn's Disease: First Anniversary Clinical Experience
Cohen, R. D., Tsang, J. F., & Hanauer, S. B. (2000) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.03363.x · Cited by 229
Self-citationVermeire, S. (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)04348-4 · Cited by 229
Self-citationAntibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease
Dejaco, C., Harrer, M., Waldhoer, T., Miehsler, W., Vogelsang, H., & Reinisch, W. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01793.x · Cited by 224
Self-citationLong-term outcome after infliximab for refractory ulcerative colitis
Ferrante, M., Vermeire, S., Fidder, H., Schnitzler, F., Noman, M., Van Assche, G., De Hertogh, G., Hoffman, I., D'Hoore, A., Van Steen, K., et al. (2008) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2008.03.004 · Cited by 223
Self-citationTaylor, K. D., Yang, H., Landers, C. J., Rotter, J. I., Targan, S. R., Plevy, S. E., & Barry, M. J. (2001) · Gastroenterology · doi:10.1053/gast.2001.23966 · Cited by 222
Self-citationHO, G. ‐., CHIAM, P., DRUMMOND, H., LOANE, J., ARNOTT, I. D. R., & SATSANGI, J. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02974.x · Cited by 218
Clinical experience with infliximab therapy in 100 patients with Crohn's disease
Farrell, R. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)02159-6 · Cited by 209
Lichtenstein, G. R., Olson, A., Travers, S., Diamond, R. H., Chen, D. M., Pritchard, M. L., Feagan, B. G., Cohen, R. D., Salzberg, B. A., Hanauer, S. B., et al. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00463.x · Cited by 202
Self-citationDixon, W. G., Watson, K. D., Lunt, M., Mercer, L. K., British Society For Rheumatology Biologics Register Control Centre Consortium, Hyrich, K. L., Symmons, D. P. M., & British Society for Rheumatology Biologics Register (2010) · Arthritis Care & Research · doi:10.1002/acr.20129 · Cited by 200
Listing, J., Strangfeld, A., Kekow, J., Schneider, M., Kapelle, A., Wassenberg, S., & Zink, A. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23281 · Cited by 195
Alvarez-Lobos, M., Arostegui, J. I., Sans, M., Tassies, D., Plaza, S., Delgado, S., Lacy, A. M., Pique, J. M., Yag??e, J., & Pan??s, J. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000186173.14696.ea · Cited by 195
LICHTENSTEIN, G. R., DIAMOND, R. H., WAGNER, C. L., FASANMADE, A. A., OLSON, A. D., MARANO, C. W., JOHANNS, J., LANG, Y., & SANDBORN, W. J. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04027.x · Cited by 195
Self-citationPredictors of early response to infliximab in patients with ulcerative colitis
Ferrante, M., Vermeire, S., Katsanos, K. H., Noman, M., Van Assche, G., Schnitzler, F., Arijs, I., De Hertogh, G., Hoffman, I., Geboes, K., et al. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20054 · Cited by 192
Self-citationArnott, I. D. R., McNeill, G., & Satsangi, J. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01574.x · Cited by 192
Jess, T., Winther, K. V., Munkholm, P., Langholz, E., & Binder, V. (2002) · Gastroenterology · doi:10.1053/gast.2002.33632 · Cited by 191
Lozeron, P., Denier, C., Lacroix, C., & Adams, D. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.11 · Cited by 190
Fistulating Anal Crohn's Disease: Results of Combined Surgical and Infliximab Treatment
Hyder, S. A., Travis, S. P. L., Jewell, D. P., McC. Mortensen, N. J., & George, B. D. (2006) · Diseases of the Colon & Rectum · doi:10.1007/s10350-006-0656-5 · Cited by 171
Self-citationOverall and cause-specific mortality in Crohnʼs disease: A meta-analysis of population-based studies
Duricova, D., Pedersen, N., Elkjaer, M., Gamborg, M., Munkholm, P., & Jess, T. (2010) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21007 · Cited by 165
Genetic Risk Profiling and Prediction of Disease Course in Crohn's Disease Patients
Henckaerts, L., Steen, K. V., Verstreken, I., Cleynen, I., Franke, A., Schreiber, S., Rutgeerts, P. J., & Vermeire, S. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.05.001 · Cited by 165
Self-citationInfliximab Improves Quality of Life in Patients with Crohn's Disease
Lichtenstein, G. R., Bala, M., Han, C., DeWoody, K., & Schaible, T. (2002) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200207000-00001 · Cited by 165
Papadakis, K. A., Shaye, O. A., Vasiliauskas, E. A., Ippoliti, A., Dubinsky, M. C., Loane, J., Paavola, J., Lee, S. K., Price, J., Targan, S. R., et al. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.40647.x · Cited by 161
Self-citationBudesonide for maintenance of remission in Crohn's disease
Kuenzig, M. E., Rezaie, A., Seow, C. H., Otley, A. R., Steinhart, A. H., Griffiths, A. M., Kaplan, G. G., & Benchimol, E. I. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002913.pub3 · Cited by 160
Radlmayr, M., Török, H., Martin, K., & Folwaczny, C. (2002) · Gastroenterology · doi:10.1053/gast.2002.34020 · Cited by 155
Sandborn, W. J., Abreu, M. T., D’Haens, G., Colombel, J., Vermeire, S., Mitchev, K., Jamoul, C., Fedorak, R. N., Spehlmann, M. E., Wolf, D. C., et al. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.04.021 · Cited by 152
Self-citationEsters, N., Vermeire, S., Joossens, S. B. A., Noman, M., Louis, E., Bélaïche, J., Vos, M. D., Gossum, A. M. V., Pescatore, P., Fiasse, R., et al. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05689.x · Cited by 142
Self-citationBüning, C., Genschel, J., Bühner, S., Krüger, S., Kling, K., Dignass, A. U., Baier, P., Bochow, B., Ockenga, J., Schmidt, H., et al. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.01967.x · Cited by 136
Tung, J., Loftus, E. V., Freese, D. K., El‐Youssef, M., Zinsmeister, A. R., Melton, J. L., Harmsen, S. W., Sandborn, W. J., & Faubion, W. A. (2006) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000235835.32176.85 · Cited by 133
Self-citationIncidence and clinical significance of immunogenicity to infliximab in Crohnʼs disease
Cassinotti, A., & Travis, S. P. L. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20899 · Cited by 130
Self-citationInfliximab dose intensification in Crohnʼs disease
Regueiro, M. D., Siemanowski, B., Kip, K. E., & Plevy, S. E. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20177 · Cited by 129
Self-citationSandborn, W. J., Löfberg, R., Feagan, B. G., Hanauer, S. B., Campieri, M., & Greenberg, G. R. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41992.x · Cited by 119
Self-citationAllez, M., Vermeire, S., Mozziconacci, N., Michetti, P., Laharie, D., Louis, E. J., Bigard, M., Hébuterne, X., Tréton, X., Kohn, A., et al. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04130.x · Cited by 113
Self-citationAssche, G. V., Lewis, J. D., Lichtenstein, G. R., Loftus, E. V., Ouyang, Q., Panés, J., Siegel, C. A., Sandborn, W. J., Travis, S. P. L., & Colombel, J. (2011) · The American Journal of Gastroenterology · doi:10.1038/ajg.2011.211 · Cited by 86
Self-citationOrlando, A., Colombo, E. M., Kohn, A., Biancone, L., Rizzello, F., Viscido, A., Sostegni, R., Benazzato, L., Castiglione, F., Papi, C., et al. (2005) · Digestive and Liver Disease · doi:10.1016/j.dld.2005.01.019 · Cited by 76
Schreiber, S., Reinisch, W., Colombel, J. F., Sandborn, W. J., Hommes, D. W., Li, J., Kent, J. D., & Pollack, P. (2007) · Journal of Crohn s and Colitis Supplements · doi:10.1016/s1873-9954(07)70190-8 · Cited by 70
Self-citationSandborn, W. J., Schreiber, S., Hanauer, S. B., Colombel, J., Bloomfield, R., & Lichtenstein, G. R. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.03.024 · Cited by 65
Self-citationKinney, T. P., Rawlins, M., Kozarek, R. A., France, R., & Patterson, D. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07286.x · Cited by 50
Predictors of response to infliximab in luminal Crohn's disease
Laharie, D., Salzmann, M., Boubekeur, H., Richy, F., Amouretti, M., Quinton, A., Couzigou, P., Lamouliatte, H., & Zerbib, F. (2005) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(05)80718-3 · Cited by 48
Role of genetics in prediction of disease course and response to therapy
Vermeire, S. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i21.2609 · Cited by 47
Self-citationLichtenstein, G. R., Cohen, R., Feagan, B. G., Sandborn, W. J., Salzberg, B. A., Chen, D., Turner, M., Mink, D., Broussard, D. L., & Diamond, R. H. (2008) · The American Journal of Gastroenterology · doi:10.14309/00000434-200809001-01116 · Cited by 22
Self-citationSandborn, W. J., Colombel, J., Rutgeerts, P. J., et al. (2008) · Gastroenterology · doi:10.1016/s0016-5085(08)61619-4 · Cited by 8
Self-citation
Cited by
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Feagan, B. G., Rutgeerts, P., Sands, B. E., Hanauer, S., Colombel, J.-F., Sandborn, W. J., Van Assche, G., Axler, J., Kim, H.-J., Danese, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215734 · Cited by 2,888
Self-citationOrdás, I., Eckmann, L., Talamini, M., Baumgart, D. C., & Sandborn, W. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60150-0 · Cited by 2,078
Self-citationDanese, S., & Fiocchi, C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1102942 · Cited by 1,102
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Vande Casteele, N., Ferrante, M., Van Assche, G., Ballet, V., Compernolle, G., Van Steen, K., Simoens, S., Rutgeerts, P., Gils, A., & Vermeire, S. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.02.031 · Cited by 886
Self-citationOxford IBD Cohort Investigators, West, N. R., Hegazy, A. N., Owens, B. M. J., Bullers, S. J., Linggi, B., Buonocore, S., Coccia, M., Görtz, D., This, S., et al. (2017) · Nature Medicine · doi:10.1038/nm.4307 · Cited by 811
Self-citation
Metadata
- Authors
- D'Haens, G. R., Panaccione, R., Higgins, P. D. R., Vermeire, S., Gassull, M., Chowers, Y., Hanauer, S. B., Herfarth, H., Hommes, D. W., Kamm, M., Löfberg, R., Quary, A., Sands, B., Sood, A., Watermayer, G., Lashner, B., Lémann, M., Plevy, S., Reinisch, W., Schreiber, S., Siegel, C., Targan, S., Watanabe, M., Feagan, B., Sandborn, W. J., Colombel, J. F., & Travis, S.
- Venue
- American Journal of Gastroenterology
- Published
- 2011-02
- Volume
- 106
- Issue
- 2
- Pages
- 199-212
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W2105311242
- Cited by
- 409
- References
- 110
- FWCI
- 18.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.